 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...89101112131415161718...2324» |
- | Daklinza (daclatasvir) / BMS
Journal: Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major. (Pubmed Central) - Dec 6, 2019
Generic DAAs are effective and safe in TM adolescents with HCV.
- | pibrentasvir (ABT-530) / AbbVie, Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, glecaprevir (ABT-493) / AbbVie
Clinical, Journal, Real-World Evidence: Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World. (Pubmed Central) - Dec 6, 2019
These real-world data confirm low rates of early discontinuation in users of second-generation DAAs. Future research focusing on socio-economic and sex/gender issues may help further optimize care for patients with HCV.
- || Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Sustained Viral Response in Genotype 4 Chronic HCV Infected Children and Adolescents Treated with Sofosbuvir/Ledipasvir. (Pubmed Central) - Nov 28, 2019
Future research focusing on socio-economic and sex/gender issues may help further optimize care for patients with HCV. Treatment with all-oral DAAs (SOF/LED) for 12 weeks was well tolerated in Egyptian children and adolescents infected with genotype 4 HCV, with 100% SVR12 and negligible side effects.
- || Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients. (Pubmed Central) - Nov 27, 2019
Thirteen CHC patients were treated with sofosbuvir/ledipasvir, and the expression levels of NKp46 and NKG2A were tested via flow cytometry at baseline, at 2, 4, 8 and 12 weeks during the therapy and 12 and 24 weeks after the end of treatment; expression levels were compared between CHC patients and 13 healthy controls...The function of NK cells is normalized to levels in healthy controls. CD56 NK cells play an important role in this process.
- Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Efficiency of treatment in naive patients with the first genotype of chronic viral hepatitis "C" with sofosbuvir + ledipasvir combination in the industrial center of Eastern Siberia () - Nov 24, 2019 - Abstract #APDW2019APDW_1292;
There were no patients with decompensated liver cirrhosis in the examined group of individuals. Sustained virological response after 12 weeks and after 24 weeks of treatment was achieved in 100% of cases (n=188) of antiviral therapy.
- Daklinza (daclatasvir) / BMS
Distribution of Hepatitis C and Direct acting antiviral drug response in tertiary care centre of Northern India (P4) - Nov 24, 2019 - Abstract #APDW2019APDW_576;
Genotype 3 is more common as compared with genotype 1 in this demographic area. End of treatment response achieved in 98.18% cases.
- Copegus (ribavirin) / Bausch Health, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Changes in fibrosis and MELD scores in HCV positive cirrhosis after direct-acting antiviral therapy (P8) - Nov 24, 2019 - Abstract #APDW2019APDW_436;
Fifteen patients received sofosbuvir(SOF)/ledipasvir(LDV), 9 patients received SOF/LDV plus ribavirin (RBV), 7 patients received paritaprevir/ritonavir, ombitasvir plus dasabuvir (PrOD), 2 patiens received PrOD plus RBV and 2 patiens received SOF plus RBV therapy. DAAs can provide regression of fibrosis and MELD scores and noninvasive methods are useful for monitoring fibrosis in patients with HCV positive cirrhosis.
- || daclatasvir+asunaprevir+BMS 791325 FDC / BMS, beclabuvir (BMS-791325) / BMS, daclatasvir/asunaprevir (BMS-60032/BMS-790052) / BMS
Clinical, Journal, Combination therapy: Favorable outcome of retreatment by direct-acting antivirals for the hepatitis C patients with Daclatasvir plus Asunaprevir combination therapy failure. (Pubmed Central) - Nov 22, 2019
AASs were frequently observed in patients with DCV+ASV failure, but most patients achieved an SVR following re-treatment with DAAs. Although the spread of drug-resistant viruses due to unsuccessful DAA treatment was a matter of concern, most cases of DCV+ASV failure were overcome with additional treatment.
- | Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Preclinical, Journal: Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies. (Pubmed Central) - Nov 22, 2019
Applicability of the proposed method to real life situations was assessed through the analysis of four different pharmaceutical formulations and satisfactory results were obtained. Additionally, dissolution profiles of the 4 drugs were studied using the developed method.
- || ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients with Genotype 1 Hepatitis C Virus Infection and Cirrhosis. (Pubmed Central) - Nov 21, 2019
Patients with decompensated cirrhosis appear to benefit from the addition of ribavirin or extension of ledipasvir and sofosbuvir treatment to 24 weeks. ClinicalTrials.gov no: NCT10474811.
- || Cimivir-L (sofosbuvir+ledipasvir) / Gilead
The 25th Anniversary #PrixGalienCanada Innovative Product Award goes to Harvoni #HRFGALA2019. @GileadSciences (Twitter) - Nov 20, 2019
- || Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients with Hematological Malignancies Allows Early Re-start of Chemotherapy. (Pubmed Central) - Nov 19, 2019
ClinicalTrials.gov no: NCT10474811. No abstract available
- || Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients. (Pubmed Central) - Nov 19, 2019
Patient characteristics were associated with receipt of 12-week regimens among patients eligible for 8 weeks, but were not associated with reduced SVR12 after 8 weeks. Shorter treatment courses might therefore be more widely used without compromising treatment effectiveness.
- Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Treatment of cirrhotic monoinfected and HCV/HIV coinfected patients with direct acting antivirals (DAAs) (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1911;
Treatment of mono or coinfected cirrhotic patients induced a significant reduction of fibrosis and of the values of aminotransferases. The rates of SVR were very high and there were no differences between the two groups.
- Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1900;
More than half of the subjects presented a history of other STIs. HCV infection was asymptomatic in a high percentage of cases, forcing systematic screening in certain populations.
- Daklinza (daclatasvir) / BMS, lamivudine / Generic Mfg., Sovaldi (sofosbuvir) / Gilead
Treatment with DAA HIV-HCV coinfected patient with XDR-tuberculosis (Sydney) - Nov 15, 2019 - Abstract #EACS2019EACS_1502;
ARV switched on ABC/3TC/LPVr in 2017...Sofosbuvir (SOF) 400mg and Daclatasvir (DCV) 60 mg initiated in August of 2017 for 12 weeks...Patient mentioned obvious improvement in physical functioning, vitality and bodily pain.Our clinical case indicate good tolerability and safety profile of the treatment with Sofosbuvir contain DAAs and drug interactions with Delamanid and Bedaquiline in difficult-to-treat cohort of HIV-HCV-coinfected patients with XDR-tuberculosis. Importantly, treatment of HCV-infection improve outcome of co-morbidities and general health.
- Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Treatment of cirrhotic monoinfected and HCV/HIV coinfected patients with direct acting antivirals (DAAs) (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1101;
Treatment of mono or coinfected cirrhotic patients induced a significant reduction of fibrosis and of the values of aminotransferases. The rates of SVR were very high and there were no differences between the two groups.
- Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1090;
More than half of the subjects presented a history of other STIs. HCV infection was asymptomatic in a high percentage of cases, forcing systematic screening in certain populations.
- Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Treatment of cirrhotic monoinfected and HCV/HIV coinfected patients with direct acting antivirals (DAAs) (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_636;
Treatment of mono or coinfected cirrhotic patients induced a significant reduction of fibrosis and of the values of aminotransferases. The rates of SVR were very high and there were no differences between the two groups.
- Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_625;
More than half of the subjects presented a history of other STIs. HCV infection was asymptomatic in a high percentage of cases, forcing systematic screening in certain populations.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Effectiveness of the Treatment of Chronic Hepatitis C Virus Infection Genotype 2 by the Combination Sofosbuvir/Ledipasvir in a Black African Kidney Transplant. (Pubmed Central) - Nov 14, 2019
Sustained virologic response 12 weeks and 24 weeks off therapy was observed. This is the first documented case of successful treatment of a genotype 2 viral C infection based on Sofosbuvir/Ledipasvir in a black African cirrhotic kidney transplant patient undergoing immunosuppressive therapy.
- ||| Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Adverse events: I don't have diabetes but I got polyneuropathy and my neurologist thinks it's due to a side effect of harvoni! (Twitter) - Nov 9, 2019
- Rituxan (rituximab) / Roche, Biogen
Effect of Active Hepatitis C Infection in Relapse-Free Survival Among Patients with HIV‐Related Diffuse Large B‐Cell Lymphoma (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5869;
Active HCV seems to play a role in the outcomes of patients treated for DLBCL and was found to be a predictor for relapse . Hence, HCV treatment should be considered for patients with HIV-related DLBCL.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. (Pubmed Central) - Nov 6, 2019
In the ION-4 trial, hepatitis C virus relapse was rare, occurring only in African American patients, 80% receiving efavirenz for human immunodeficiency virus infection. We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Shoulda gone for a compulsory license, generic SOF/LED (Harvoni) is only a couple of hundred pounds... another country fleeced by @GileadSciences... (Twitter) - Nov 1, 2019
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. (Pubmed Central) - Oct 31, 2019
We observed no indication that CYP2B6 polymorphisms associated with increased plasma efavirenz exposure explained the relapses. In our study of patients with HCV and isolated hepatitis B core or HBsAg positivity, no HCV patients treated with DAA experienced HBV reactivation.
- | Journal, Adverse drug reaction: Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database. (Pubmed Central) - Oct 28, 2019
Moreover, significant adjusted RORs for hypoacusis regarded clarithromycin (3.95, 1.86-8.40), azithromycin (10.23, 5.03-20.79), vancomycin (6.72, 2.14-21.11), methotrexate (3.13, 1.00-9.81), pemetrexed (4.38, 1.40-13.76), vincristine (5.93, 1.88-18.70), vinorelbine (21.60, 8.83-52.82), paclitaxel (2.34, 1.03-5.30), rituximab (3.20, 1.19-8.63), interferon alfa-2b (17.44, 8.56-35.53), thalidomide (16.92, 6.92-41.38), and deferasirox (41.06, 20.07-84.01)...Hypoacusis after the use of vinorelbine, methotrexate, and pemetrexed is unexpected, such as tinnitus related with etoposide, nebivolol, betamethasone, abatacept, sofosbuvir/ledipasvir, and tapentadol, but these considerations require further investigation to better define the risk due to the paucity of data. Moreover, physicians should be aware of the clinical significance of ototoxicity and be conscious about the importance of their contribution to spontaneous reporting.
- | Copegus (ribavirin) / Bausch Health, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series. (Pubmed Central) - Oct 25, 2019
Moreover, physicians should be aware of the clinical significance of ototoxicity and be conscious about the importance of their contribution to spontaneous reporting. DAA therapy in HCV patients off IS post-LT can be successfully undertaken without need to restart IS.
- | Avelox (moxifloxacin) / Bayer
Clinical, Journal: A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects. (Pubmed Central) - Oct 24, 2019
Ledipasvir does not prolong QTc interval. Based on these results and a previous TQT evaluation for sofosbuvir, the fixed-dose combination regimen of ledipasvir/sofosbuvir is not expected to prolong the QTc interval.
- | tenofovir disoproxil fumarate / Generic Mfg.
Clinical, PK/PD data, Journal: Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. (Pubmed Central) - Oct 24, 2019
These data indicate an unexpected drug interaction with tenofovir disoproxil fumarate and sofosbuvir at the cellular level. Additional studies are needed to determine the mechanism and clinical significance.
- | pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Ledipasvir and sofosbuvir for 12 weeks for HCV genotype 2 infection: A propensity score matched analysis. (Pubmed Central) - Oct 22, 2019
Treatment with LDV/SOF for HCV GT2 resulted in a high rate of SVR12 and excellent tolerability. The outcomes of the LDV/SOF were very similar to those of the GLE/PIB.
- | Daklinza (daclatasvir) / BMS
Clinical, Journal, IO Biomarker: Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder. (Pubmed Central) - Oct 20, 2019
Although adherence was slightly worse than in "usual" patients, it did not affect the SVR rate. In these difficult-to-manage patients with HCV and substance use disorder, the real-world SVR rate (90%) was similar to that in nonaddicted populations.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report. (Pubmed Central) - Oct 19, 2019
Clinicians should be aware that sexual dysfunction is a possible side effect of ledipasvir/sofosbuvir and educate patients appropriately. Adherence should be emphasized as the risks of untreated hepatitis C virus far outweigh transient sexual dysfunction.
- | Olysio (simeprevir) / J&J, Medivir, ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. (Pubmed Central) - Oct 18, 2019
Pooled analysis of all patients with baseline RASs revealed that SVR12 was 100% (19/19) in patients treated for longer than 98 days but was 87% (81/93) in patients treated for shorter than 98 days. These results demonstrate that RASs prevalence and their impact in real world practice are in general agreement with registration trials, and suggest that longer treatment duration may overcome the negative impact of baseline RASs on SVR12 rates in clinical practice.
- | paritaprevir/ritonavir (ABT-450/r) / AbbVie, Daklinza (daclatasvir) / BMS
Clinical, Review, Journal: Direct-acting antivirals for children and adolescents with chronic hepatitis C. (Pubmed Central) - Oct 16, 2019
If and when DAAs are approved for younger age cohorts, all children older than 3 years infected with hepatitis C will benefit from antiviral therapy. In this Review, we aim to provide an up-to-date overview of the existing evidence on the paediatric use of DAAs, summarising indications to treatment and recommendations for monitoring.
- Cimivir-L (sofosbuvir+ledipasvir) / Gilead
The Cryo Menace (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1740;
We present an interesting case of persistent cryoglobulinemia and MPGN despite sustained remission of hepatitis C treated with Harvoni (direct-acting antiviral)...Treatment with immunosuppression may be warranted, if there is nephrotic range proteinuria, a reduced estimated glomerular filtration, and/or severe histologic changes such as crescents on renal biopsy. Fig A
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal, HEOR: Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection. (Pubmed Central) - Oct 11, 2019
We conclude that in East Asian patients with HCV, HRQL improved from baseline after treatment with LDV/SOF but not with Peg-IFN+RBV-containing or Peg-IFN-free RBV-containing regimens. The HRQL impairment associated with the use of Peg-IFN persists even after achieving sustained virologic clearance.
- | Daklinza (daclatasvir) / BMS
Journal: Sofosbuvir with NS5A Inhibitors in Hepatitis C Virus (HCV) Infection with Severe Renal Insufficiency. (Pubmed Central) - Oct 11, 2019
Therapy was very well accepted. Full dose sofosbuvir with NS5A inhibitors is a well tolerated and effective therapy for HCV infection in severe renal insufficiency.
- | Copegus (ribavirin) / Bausch Health, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Findings from a large asian chronic hepatitis c real life study. (Pubmed Central) - Oct 11, 2019
In conclusion, patients with GT1 and 3 with/without cirrhosis had surprisingly high efficacy using SR, suggesting that Asians may respond better to some DAAs. However, poor GT6 response to SL suggests this regimen is suboptimal for this genotype.
- | pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, daclatasvir/asunaprevir (BMS-60032/BMS-790052) / BMS
Clinical, Journal: Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. (Pubmed Central) - Oct 11, 2019
Our population represented an elderly demographic, with a high prevalence of comorbidities and widespread use of concomitant medications. The potential drug-drug interactions between these concomitant medications and DAA regimens differed, with the fewest potential interactions with sofosbuvir-based regimens.
- | sofosbuvir/velpatasvir/voxilaprevir (GS-7977/GS-5816/GS-9857) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta
Review, Journal: Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir. (Pubmed Central) - Oct 10, 2019
The potential drug-drug interactions between these concomitant medications and DAA regimens differed, with the fewest potential interactions with sofosbuvir-based regimens. The addition of SOF/VEL/VOX and G/P to existing hepatitis C treatment options will expand the number of patients who are eligible for and responsive to treatment, thus increasing the possibility of eliminating hepatitis C as a public health issue.
- | paritaprevir/ritonavir (ABT-450/r) / AbbVie
Journal: State of viral hepatitis care in 16 countries of Central and Eastern European Region. (Pubmed Central) - Oct 10, 2019
Despite the availability of registered modern drugs for HCV and HBV, the access to treatment is limited. Ensuring quality health care is essential to reduce the epidemic and achieve the WHO's goal of eliminating viral hepatitis as a major public health challenge.
- | paritaprevir/ritonavir (ABT-450/r) / AbbVie
Journal: Differential timing of cholesterol increase during successful HCV therapy: impact of type of drug combination. (Pubmed Central) - Oct 9, 2019
Ensuring quality health care is essential to reduce the epidemic and achieve the WHO's goal of eliminating viral hepatitis as a major public health challenge. Our study suggests that the differential timing of the restoration of cholesterol metabolism in HIV/HCV genotype 1 co-infected patients achieving SVR is not mediated by HCV clearance but depends on the drug combination employed.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Review, Journal: Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir. (Pubmed Central) - Oct 9, 2019
As a perpetrator of pharmacokinetic drug-drug interactions via P-glycoprotein/BCRP, ledipasvir/sofosbuvir should not be used with rosuvastatin and elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, whereas its co-administration with amiodarone is not recommended because of a pharmacodynamic interaction. This review summarizes a number of drug interaction studies conducted in support of the clinical development of ledipasvir/sofosbuvir.
- | Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: HCV phylogenetic Signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. (Pubmed Central) - Oct 8, 2019
This review summarizes a number of drug interaction studies conducted in support of the clinical development of ledipasvir/sofosbuvir. Differences in the prevalence of GT2 and GT3 subtypes and NS5A RAS were observed between Asian and Western countries.
- Cimivir-L (sofosbuvir+ledipasvir) / Gilead
ACHIEVEMENT OF SVR WITH LEDIPASVIR/SOFOSBUVIR THERAPY IN PATIENTS WITH HEPATITIS C AND MODERATE CHRONIC KIDNEY DISEASE MAY LEAD TO IMPROVED KIDNEY FUNCTION. (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2999;
In patients with HCV who underwent 12-week therapy with LED/SOF and achieved SVR there were no significant differences in renal function after therapy. HCV patients with moderate chronic kidney disease treated with LED/SOF may preferentially show improvements in renal function if they achieve SVR.
- daclatasvir/asunaprevir (BMS-60032/BMS-790052) / BMS
ALTERED microRNA EXPRESSION PROFILES IN SERUM EXOSOME LINKS TO CLINICAL PHENOTYPES INDUCED BY DIRECT-ACTING ANTIVIRAL THERAPY (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2940;
In a pilot study, we employed qPCR arrays using with specific primers of 792 miRNAs t o analyze change in the profiles of exosomal miRNA in serum of the five paired samples before and after daclatasvir and asunaprevir combination therapy...This tendency was also observed in patients treated with the ledipasvir/sofosbuvir... The current findings indicate the changes in serum exosomal miRNA of SVR pts might account for the clinical phenotypes and would contribute to early detection of the adverse events in SVR pts.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, Daklinza (daclatasvir) / BMS
CLINICAL EFFICACY AND SAFETY OF DIRECT ACTING ANTIVIRALS FOR TREATMENT OF HEPATITIS C VIRUS RECURRENCE AFTER LIVER TRANSPLANTATION (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2717;
Positive HCV-PCR at TW4 and genotype 3 are strong predictors of Tx failure in post-LT patients. Future validation in a multi-center larger sample is warranted.
- Daklinza (daclatasvir) / BMS
DECENTRALIZED CARE FOR CHRONIC HEPATITIS C FOR PERSONS WHO INJECT DRUGS USING ALL GENERIC DIRECT-ACTING ANTIVIRALS IS FEASIBLE, SAFE AND EFFECTIVE (Sheraton Boston Hotel, Constitution Ballroom) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2586;
P2/3
Treatment interruptions are more common in PWID patients; measures for reducing treatment interruptions are important for improving treatment outcomes. (ClinicalTrials.gov number: NCT01110447)
- Daklinza (daclatasvir) / BMS
DECENTRALIZED CARE WITH ALL GENERIC DIRECT-ACTING ANTIVIRALS IN THE MANAGEMENT OF CHRONIC HEPATITIS C IN A PUBLIC HEALTH CARE SETTING: FINAL RESULTS OF MMPHCRF, PUNJAB, INDIA (Hynes Convention Center, Hall B) - Sep 29, 2019 - Abstract #AASLD2019AASLD_2585;
P2/3
The Mukh-Mantri Punjab Hepatitis C Relief Fund (MMPHCRF), launched on 18 June 2016, provides no-cost generic direct-acting antivirals (DAAs) with sofosbuvir+ledipasvir±ribavirin or sofosbuvir+daclatasvir±ribavirin with the goal to eliminate CHC in Punjab. Decentralized care of CHC with generic all oral DAAs regimens is safe and effective regardless of genotype or presence of cirrhosis.(ClinicalTrials.gov number:NCT01110447)